Results 31 to 40 of about 3,587 (149)
Preferences between three options for androgen deprivation therapy: a focus group study
BJU International, Volume 136, Issue 6, Page 1037-1047, December 2025.Objectives Androgen deprivation therapy (ADT) forms the mainstay of treatment for advanced prostate cancer. Traditionally administered as a luteinising hormone‐releasing hormone (LHRH) agonist depot injection, newer options for ADT include transdermal oestradiol patches (tE2) or oral LHRH antagonists.
Hannah L. Rush +13 more
wiley +1 more source
The presence of LHRH‐like receptors in Dunning R3327H prostate tumors
FEBS Letters, 1983 Quantitative analyses of LH‐RH‐like membrane receptors were performed in five tumors from the transplantable Dunning R3372H rat prostatic adenocarcinoma. The binding of D‐Trp6‐LH‐RH, an agonist of LH‐RH, was observed in all 5 tumors. The antagonist [Ac‐Dp‐Cl‐Phe1,2,D‐Trp3,D‐Lys6,D‐Ala10]‐LH‐RH was bound to 4 tumors.
Hierowski, Marion T. +3 more
openaire +2 more sources
EFSA Journal, Volume 23, Issue 12, December 2025.Abstract According to the ‘EFSA‐SANTE Action Plan on Cumulative Risk Assessment for pesticides residues’, EFSA, with the support of a working group, undertook the identification of specific effects on male and female reproductive function, including fertility, that are considered relevant for grouping pesticide residues and for assessing ...
European Food Safety Authority (EFSA) +10 more
wiley +1 more source
The contemporary management of prostate cancer
CA: A Cancer Journal for Clinicians, Volume 75, Issue 6, Page 552-586, November/December 2025.Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden.
Deep Chakrabarti +11 more
wiley +1 more source
Advances in Inhaled Nanoparticle Drug Delivery for Pulmonary Disease Management
The FASEB Journal, Volume 39, Issue 21, 15 November 2025.Pulmonary disorders remain a global health challenge. This review explores critical innovations in inhaled nanoparticle drug delivery systems focusing on their potential to revolutionize treatment strategies for a wide spectrum of pulmonary diseases. We highlight recent breakthroughs in carrier materials, performance evaluations in vitro and in vivo ...
Yunzhou Fan +3 more
wiley +1 more source
Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta‐Analysis
The Prostate, Volume 85, Issue 15, Page 1395-1411, November 2025.ABSTRACT Background Patients with prostate cancer (PC) invading into the seminal vesicles (SV) constitute a specific subgroup of high‐risk patients (staged as T3b) with a particularly high risk of disease recurrence, even when lymph node or distant metastases are absent (N0M0).
Casper Reijnen +8 more
wiley +1 more source
International Journal of Urology, Volume 32, Issue 11, Page 1640-1649, November 2025.ABSTRACT Objectives Treatment strategies for metastatic castration‐sensitive prostate cancer (mCSPC) have advanced significantly, yet the prognostic impact of time to castration resistance (TTCR) on overall survival (OS) remains unclear. This retrospective study aimed to evaluate the relationship between TTCR and OS.
Hiroaki Iwamoto +12 more
wiley +1 more source
Promising Prodiginins Biological Activities
Chemistry &Biodiversity, Volume 22, Issue 9, September 2025.ABSTRACT Prodiginins are a large family of at least 34 pyrrolic compounds, including the well‐studied red pigment prodigiosin. Prodiginins are produced by several microorganisms displaying broad biological activities, including antimicrobial, antiviral, antiparasitic, antiproliferative, and immunosuppressive activities.
María F. Ladetto +6 more
wiley +1 more source
Cancer Medicine, Volume 14, Issue 15, August 2025.ABSTRACT Introduction Aromatase inhibitor (AI) therapy reduces breast cancer recurrence risk. However, some patients stop treatment early because of AI‐associated musculoskeletal symptoms (AIMSS). AIMSS is due in part to systemic inflammation. Cannabidiol (CBD) has anti‐nociceptive and anti‐inflammatory properties, making it a potential treatment ...
Nicole M. G. Fleege +8 more
wiley +1 more source
Endocrinologia Japonica, 1986 The effects of an LHRH agonist (LHRHa), [D-Ser (tBu)]6 des-Gly-NH210) ethylamide, on endocrine function and the LHRH and LH/hCG receptors in the pituitary-gonadal axis were examined. The LHRHa was injected at 100 ng/100 g body weight into male rats once a day for 4 weeks and its effects were observed until 2 weeks after the end of treatment.
M, Komatsu, H, Iwahana, S, Mitsuhashi
openaire +3 more sources